ANN ARBOR, Mich. — Ange Bradley paced back and forth, rolling a ball across the top of Ocker Field before the start of the national championship game. After the University of Michigan received a record 10.7 inches of snow the day before, Bradley wanted to see how the ball played across the wet and cold blue surface — very much entrenched in the present.Her 2015 Orange sat little over an hour away from its biggest game and Bradley wanted nothing left to chance, not even the slightest bounce. The team preparing in the locker had been engineered the very same way, piece by piece and with little to no room for uncertainties.But after 70 minutes of play and amid the national championship celebration, Bradley was finally able to remove herself from the moment, look back on her achievements and realize exactly what she had accomplished.Lifted far above the rest of the festivities occurring at midfield by her backs Lies Lagerweij and Roos Weers, Ange Bradley looked at her team — the first women’s national championship team in Syracuse history — and simply smiled.“I’m numb. I’ve been chasing this dream for 25 years,” Bradley said. “… I have no feeling because it’s so unreal. I’m just so proud of these women.”AdvertisementThis is placeholder textNow finished with her ninth season as Syracuse field hockey’s head coach, Bradley has led the Orange to eight straight NCAA tournaments, four final fours and now two national championship games. But until Syracuse (21-1, 6-0 Atlantic Coast) defeated North Carolina (21-3, 4-2), 4-2, Sunday, the biggest achievement had always eluded her.When things looked bleakest in the title game after two North Carolina goals tied the game, Bradley helped turn the tide with a crucial timeout.“(A motivating time out) is all it is at this time,” Bradley said. “There’s tactics obviously, but great players make plays and it’s keeping the confidence high and keeping positive and keeping the belief and staying in the moment.”Following the timeout, Syracuse looked recharged and began to play more like the team that scored two goals in the game’s first 18 minutes. After earning a penalty corner, Syracuse netted its third goal of the game to break the tie and pull away from the Tar Heels.It all began after falling 1-0 to Connecticut in the 2014 national championship. Bradley set her sights on architecting a team that could once again reach field hockey’s biggest stage.SU returned 71 percent of its total scoring from last year, but retooled with the additions of Dutch graduate student Alma Fenne (47 points), Northeastern and second-team All American transfer Emma Lamison (22) and freshman starting backs Roos Weers (37) and Wilson (four).Bradley moved 2014 starting forwards Laura Hurff and Lies Lagerweij to midfielder and center back, respectively. Liz Sack left her reserve role and started the season’s final five games after Bradley saw promise in her forward play in the ACC tournament semifinal. As a result, Sack added nine points in the Orange’s four-game NCAA tournament run.For Bradley, the focus didn’t ever rest on one player. Making Syracuse the best team possible was the only thing that mattered.On Sunday, Bradley’s team wasn’t just the best it could be. Syracuse cemented itself as the best team in the country.“(Bradley’s) game plan every time has been incredible,” Emma Russell said. “I don’t think there’s a coaching staff that deserves it more than ours.” Comments Published on November 22, 2015 at 9:13 pm Contact Liam: firstname.lastname@example.org Related Stories Syracuse field hockey becomes 1st women’s team in school history to win national championshipJess Jecko’s late saves help lead Syracuse to national championship winEmma Russell sets points record en route to national championship winGallery: Syracuse field hockey wins national titleStorify: Fans react to Syracuse field hockey’s first national title Facebook Twitter Google+
Source:https://ki.se/en/news/anti-inflammatory-strategy-stops-aggressive-childhood-cancer May 28 2018Researchers at Karolinska Institutet and Karolinska University Hospital have discovered that an anti-inflammatory drug candidate inhibiting the prostaglandin E2 producing enzyme mPGES-1 in the tumor stroma reduces tumor growth in experimental neuroblastoma models. The findings are published in EBioMedicine and open for new treatment strategies for this aggressive childhood cancer.”High-risk neuroblastoma is the most common and deadly cancer in infants. Novel therapies are highly warranted, in particular if they improve survival without adding adverse side effects,” says Professor Per Kogner at Karolinska Institutet’s Department of Women’s and Children’s Health, who led the study together with Professor Per-Johan Jakobsson at Karolinska Institutet’s Department of Medicine, Solna.Related StoriesSugary drinks linked to cancer finds studyStudy reveals link between inflammatory diet and colorectal cancer riskHow cell-free DNA can be targeted to prevent spread of tumorsNeuroblastoma is an aggressive nerve cell tumor which is diagnosed early, often before two years of age, and is stratified into different risk categories: low-risk, intermediate-risk and high-risk. Children with high-risk neuroblastoma receive intensive multi-modal treatment that has increased survival over the years but survivors both have high risk of life-threatening relapse and severe life-long side effects. Targeting of the stromal compartment has been suggested as a new strategy to increase survival further and to increase the quality of life of children who survive the disease.Targeting benign cells”We found that the dominant cell type in the tumor stroma, benign cancer-associated fibroblasts, were the main producers of prostaglandin E2 in neuroblastoma,” says Anna Kock, PhD at the Department of Women’s and Children’s Health and first author of the study. “These normal cells support the growth of cancer cells and should be targeted since they are more genetically stable than the malignant cells, and therefore less prone to develop resistance.”Assistant professor Karin Larsson at the Department of Medicine, Solna, who has worked on the project for several years, explains:”Prostaglandin E2 not only mediates fever and pain, but also drives inflammation in the tumors, promoting tumor growth. Inhibition of the enzyme mPGES-1, that catalyzes the production of prostaglandin E2, resulted in reduced tumor growth in experimental neuroblastoma models.”The researchers believe that the finding could lead to improved survival with fewer side effects for children with neuroblastoma.Begin to understand the mechanisms”mPGES-1 is an emerging target for treatment of inflammation and pain with cardioprotective properties. NSAIDs, which result in reduced prostaglandin levels, have long been implicated as prophylaxis against certain cancers. Our present study pinpoints mPGES-1 in neuroblastoma and we now begin to understand the mechanisms behind its involvement in cancer growth,” says Professor Per-Johan Jakobsson, who discovered mPGES-1.